Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
June 10, 2020
Umeå Biotech Incubator

HiloProbe attracts millions in new investment round

HiloProbe attracts millions in new investment round

Marie-Louise Hammarström, Sten Hammarström, Anne Israelsson, Gudrun Lindmark, Harald Hedman, Lina Olsson, Linn Heikkilä at HiloProbe.

Umeå biotech company HiloProbe has attracted millions in new investment capital after successfully developing a diagnostic and prognostic product for colon and rectal cancer.

“Capital is crucial for getting our product to patients and helping them,” says Lina Olsson, HiloProbe’s CEO.

HiloProbe has developed a product called ColoNode that is used for the diagnosis and prognosis of colon and rectal cancer by identifying tumor cells in lymph nodes and measuring their aggressiveness. This analysis is performed following surgery and the information it provides, in combination with other test results, can indicate if the patient requires further treatment or whether surgery alone has been curative. The analysis is more accurate than current routine methods.

“Our goal is that more patients will survive," says Lina Olsson, CEO of HiloProbe.

The company had already received capital investment from Partnerinvest Norr and Northern Light Capital, together with a number of private investors. Now, after reaching agreed milestones, the same investors are contributing millions more in finance.

“It feels fantastic that our investors believe in the company and our product. This capital is crucial for our product to reach patients in the future and to be used in hospitals,” says Lina Olsson.

HiloProbe has now developed its first market-ready product that will be sold to cancer researchers. The new capital will be used to launch the product and guarantee the completion of an ongoing clinical study that is needed for a CE marking of the product. The CE marking is planned for completion next year.

For more information, please contact:

Lina Olsson, CEO of HiloProbe

076-821 67 70

lina.olsson@hiloprobe.se

Last updated:
June 10, 2020

Umeå Biotech Incubator

Umeå Biotech Incubator is Sweden’s only life science incubator established by rebellious scientists. Today we have grown up to become a state of the art biotech incubator offering facilities, know-how and financing. We have been named one of Europe’s top 15 biotech incubators and we are aiming to become the best.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

Marie-Louise Hammarström, Sten Hammarström, Anne Israelsson, Gudrun Lindmark, Harald Hedman, Lina Olsson, Linn Heikkilä at HiloProbe.

Umeå biotech company HiloProbe has attracted millions in new investment capital after successfully developing a diagnostic and prognostic product for colon and rectal cancer.

“Capital is crucial for getting our product to patients and helping them,” says Lina Olsson, HiloProbe’s CEO.

HiloProbe has developed a product called ColoNode that is used for the diagnosis and prognosis of colon and rectal cancer by identifying tumor cells in lymph nodes and measuring their aggressiveness. This analysis is performed following surgery and the information it provides, in combination with other test results, can indicate if the patient requires further treatment or whether surgery alone has been curative. The analysis is more accurate than current routine methods.

“Our goal is that more patients will survive," says Lina Olsson, CEO of HiloProbe.

The company had already received capital investment from Partnerinvest Norr and Northern Light Capital, together with a number of private investors. Now, after reaching agreed milestones, the same investors are contributing millions more in finance.

“It feels fantastic that our investors believe in the company and our product. This capital is crucial for our product to reach patients in the future and to be used in hospitals,” says Lina Olsson.

HiloProbe has now developed its first market-ready product that will be sold to cancer researchers. The new capital will be used to launch the product and guarantee the completion of an ongoing clinical study that is needed for a CE marking of the product. The CE marking is planned for completion next year.

For more information, please contact:

Lina Olsson, CEO of HiloProbe

076-821 67 70

lina.olsson@hiloprobe.se

Last updated:
June 10, 2020

Umeå Biotech Incubator

Umeå Biotech Incubator is Sweden’s only life science incubator established by rebellious scientists. Today we have grown up to become a state of the art biotech incubator offering facilities, know-how and financing. We have been named one of Europe’s top 15 biotech incubators and we are aiming to become the best.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail